androgen replacement therapy

Also found in: Wikipedia.

androgen replacement therapy

The administration of androgens (e.g., testosterone or its congeners) in men with hypogonadal androgen-deficiency, which may be primary or secondary and either congenital or acquired. The intent of ART is to restore normal physiologic effects of testosterone, which depend on the stage of sexual development.

In androgen-deficient boys, the goal of ART is to initiate and maintain androgen-dependent activities, including somatic development (e.g., development of skeletal muscle and increased strength, long bone growth, redistribution of body fat and erythropoiesis), sexual behaviour (increased libido and potency) and development of 2º sexual characteristics (e.g., male pattern of hair growth, penile and scrotal enlargement, laryngeal enlargement and thickening of the vocal cords, and deepening of the voice).

Androgen replacement therapies 
The oral testosterones available in the US are methyl testosterone and fluoxymesterone; both are nonphysiological, 17-alkylated molecules with hepatotoxic potential.
Well-absorbed physiologic testosterone.

Inconvenience of shaving scrotal skin; impregnation of patches with absorption enhancers, such as alcohol, allows their application to nongenital skin, but causes local irritation in up to 53% of patients.
Absorbed physiologic testosterone.


Sublingual AndroTest-SL®
Convenience; physiologic testosterone.

References in periodicals archive ?
In view of the emerging evidence suggesting that androgen deficiency is a risk factor for CVD, androgen replacement therapy could potentially reduce CVD risk in hypogonadal men.
Thus, the authors suggest that androgen replacement therapy might one day be used to treat men at risk for heart disease.
Long-term risks of androgen replacement therapy are still unknown, according to Sokol
Jiangang Chen, University of California at Davis, and colleagues announced that they have made headway in understanding the importance of endogenous androgens and the benefits and risks of exogenous androgen replacement therapy in women during menopausal transition through a newly developed cell-based androgen bioassay in serum sampled from 100 mid-aged women (42-58 years old) from SWAN (Study of Women's Health Across the Nation).
No androgen replacement therapy is currently approved in the United States for women.
No androgen replacement therapy is approved in the United States for women.
Women with sexual dysfunction whose free testosterone levels are in the bottom third of the normal range or below normal should be considered for a trial of androgen replacement therapy, Dr.
If no, consider a trial of androgen replacement therapy.
No androgen replacement therapy is currently approved in the United States for women, and the panel suggested that physicians offering testosterone supplementation or DHEAS off label should regularly assess their patient's health in light of potential risks, including lipid changes, estrogenic effects, and effects on the mood, voice, and skin.
Analysts have indicated they expect the market for androgen replacement therapy for men to exceed $1 billion in annual sales in North America within five years.
Androgen replacement therapy could help prevent the development of Alzheimer's disease, report scientists in the Journal of Neuroscience.
TORONTO -- Dehydroepiandrosterone may have potential as a combined estrogen and androgen replacement therapy, Dr.

Full browser ?